Earnings playbook: Alphabet, Microsoft, Amazon earnings this week
Earnings season is in full swing, and more tech giants are slated to report in the new week…
Biotech stocks rally on drug innovation and M&A
Moderna gave investors a scare as its stock plunged on Thursday. But it’s still one of the hottest…
Next week brings major risks for the stock market, just as the AI trade keeps faltering
Next week will bring major risks for a stock market that’s trying to find its footing as the…
AI stocks plunge. Inflation heats up. Where we’re still finding opportunities
The sinking AI trade and hotter-than-expected inflation data rattled last week’s stock market. But solid bank earnings and…
Eli Lilly obesity drug with amylin, tirzepatide boosts weight loss in trial
Eli Lilly on Wednesday said its experimental combination regimen resulted in greater weight loss than a high dose…
Nvidia approaches a breakout level. Plus, what we want to see from Micron
Every weekday, the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET.…
Novo’s Wegovy pill improves weight loss after switch from injections
People who switched from obesity injections to Novo‘s new Wegovy pill continued to lose weight after three months,…
Nvidia says it can control AI models — plus, how to act on Boeing’s dip
Every weekday, the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET.…
Pharma stock soars 150% on injectables deal with Wegovy maker Novo
Michael Siluk | UCG | Universal Images Group | Getty Images Shares in Swedish microcap stock Nanexa more…
Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…
Novo Nordisk CEO on rebuilding investor trust after backlash
Novo Nordisk CEO Maziar Mike Doustdar waits for the start of the pharmaceutical company’s annual general meeting in…
Eli Lilly CEO David Ricks discusses GLP-1s and Medicare coverage
Eli Lilly CEO Dave Ricks told CNBC on Monday that 700,000 new seniors have started GLP-1 treatments since…